Osteonecrosis of the Jaw: More Research Needed

Osteonecrosis of the jaw: more research needed.

In the past 2 years, an increasing number of reports have appeared in the medical literature that suggest that the use of bisphosphonates, especially intravenous bisphosphonates, is associated with osteonecrosis of the jaw (ONJ). The majority of these reports are in patients with multiple myeloma, breast cancer, or other malignancies. In connection with these malignancies, the patients were rec...

Osteonecrosis of the jaw: more heat than light.

Osteonecrosis of the jaw has received a great deal of attention in the past few years. The earliest case reports claimed that the only time it ever occurred was as a complication of therapy with bisphosphonates and that both oral and intravenous bisphosphonates were implicated (1). These reports led to use of terms such as BRONJ (bisphosphonate-related osteonecrosis of the jaw). The speculation...

[Osteonecrosis of the jaw].

The paper concerns osteonecrosis of the jaw (ONJ). It is a rare but serious clinical condition. It can develop in patients treated in oncologic doses with bisphosphonates but also with denosumab. In osteoporosis ONJ seems to be very rare. Definition, pathogenesis, risk factors, prevention and treatment, and the frequency of ONJ are presented.

Animal models of osteonecrosis of the jaw.

Bevacizumab-associated osteonecrosis of the jaw.